dc.contributor.authorGuo, Ke
dc.contributor.authorTang, Jing Ping
dc.contributor.authorJie, Li
dc.contributor.authorAl-Aidaroos, Abdul Qader O.
dc.contributor.authorHong, Cheng William
dc.contributor.authorTan, Cheng Peow Bobby
dc.contributor.authorPark, Jung Eun
dc.contributor.authorVarghese, Leyon
dc.contributor.authorFeng, Zhiwei
dc.contributor.authorZhou, Jianbiao
dc.contributor.authorChng, Wee Joo
dc.contributor.authorZeng, Qi
dc.date.accessioned2013-07-04T02:28:12Z
dc.date.available2013-07-04T02:28:12Z
dc.date.copyright2012en_US
dc.date.issued2012
dc.identifier.citationGuo, K., Tang, J. P., Jie, L., Al-Aidaroos, A. Q. O., Hong, C. W., Tan, C. P. B., et al. (2012). Engineering the First Chimeric Antibody in Targeting Intracellular PRL-3 Oncoprotein for Cancer Therapy in Mice. Oncotarget, 3(2), 158-171.en_US
dc.identifier.issn1949-2553en_US
dc.identifier.urihttp://hdl.handle.net/10220/10924
dc.description.abstractAntibodies are considered as ‘magic bullets’ because of their high specificity. It is believed that antibodies are too large to routinely enter the cytosol, thus antibody therapeutic approach has been limited to extracellular or secreted proteins expressed by cancer cells. However, many oncogenic proteins are localized within the cell. To explore the possibility of antibody therapies against intracellular targets, we generated a chimeric antibody targeting the intracellular PRL-3 oncoprotein to assess its antitumor activities in mice. Remarkably, we observed that the PRL-3 chimeric antibody could efficiently and specifically reduce the formation of PRL-3 expressing metastatic tumors. We further found that natural killer (NK) cells were important in mediating the therapeutic effect, which was only observed in a nude mouse model (T-cell deficient), but not in a Severe Combined Immunodeficiency’ (scid) mouse model (B- and T-cell deficient), indicating the anticancer effect also depends on host B-cell activity. Our study involving 377 nude and scid mice suggests that antibodies targeting intracellular proteins can be developed to treat cancer.en_US
dc.language.isoenen_US
dc.relation.ispartofseriesOncotargeten_US
dc.rights© 2012 The Authors. This paper was published in Oncotarget and is made available as an electronic reprint (preprint) with permission of The Authors. The paper can be found at the following official open URL: [http://www.ncbi.nlm.nih.gov.ezlibproxy1.ntu.edu.sg/pmc/articles/PMC3326646/]. One print or electronic copy may be made for personal use only. Systematic or multiple reproduction, distribution to multiple locations via electronic or other means, duplication of any material in this paper for a fee or for commercial purposes, or modification of the content of the paper is prohibited and is subject to penalties under law.en_US
dc.subjectDRNTU::Science::Biological sciences
dc.titleEngineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in miceen_US
dc.typeJournal Article
dc.contributor.schoolSchool of Biological Sciencesen_US
dc.identifier.openurlhttp://www.ncbi.nlm.nih.gov.ezlibproxy1.ntu.edu.sg/pmc/articles/PMC3326646/
dc.description.versionPublished versionen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record